Michael Alunni, MD
Ophthalmology · Pittsburgh, PANPI 1194916825
Payments from drug & device makers
Across 243 payments — averaging $30.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- AbbVie$1K
- Ivantis, Inc$964
- NEW World Medical,inc.$525
- Aerie Pharmaceuticals, Inc.$420
- Novartis$218
- plus $919 from 16 others
What the payments were for
- Consulting fees$5007%
- Food & beverage$6,96093%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 99 | $2,938 |
| AbbVie(2 entities) | 65 | $1,477 |
| Ivantis, Inc | 20 | $964 |
| NEW World Medical,inc. | 7 | $525 |
| Aerie Pharmaceuticals, Inc. | 9 | $420 |
| Novartis | 6 | $218 |
| Biotissue Holdings Inc. | 5 | $154 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $148 |
| Regeneron Healthcare Solutions, Inc. | 5 | $109 |
| Glaukos Corporation | 3 | $86 |
| Sun Pharmaceutical Industries Inc. | 4 | $76 |
| Sight Sciences, Inc. | 4 | $59 |
| Kala Pharmaceuticals, Inc. | 3 | $57 |
| Oyster Point Pharma, Inc. | 2 | $46 |
| Rxsight Inc | 1 | $41 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Amgen | 1 | $25 |
| Shire North American Group Inc | 1 | $23 |
| Thea Pharma Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Johnson & Johnson Vision Care, Inc. | 1 | $16 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus$500
- Ahmed Glaucoma Valve$377
- Kahook Dual Blade$377
- Clareon$265
- Hydrus Microstent$241
- XEN GLAUCOMA TREATMENT SYSTEM$236
- Rhopressa$233
- Centurion$162
- XEN$125
- Rocklatan$125
- VYZULTA$116
- TRAVATAN Z$113
- ARGOS$107
How this compares
$7,460 in reported general payments places this provider in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 75 | $37,015 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 503 | $28,069 |
| IlevroNepafenac | 30 | $10,671 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $9,569 |
| VyzultaLatanoprostene Bunod | 15 | $8,591 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $6,321 |
| ProlensaBromfenac Sodium | 14 | $4,847 |
| Brimonidine Tartrate | 26 | $3,968 |
| Tobradex StTobramycin/Dexamethasone | 14 | $3,286 |
| TafluprostTafluprost/Pf | 14 | $2,410 |
| Travoprost | 19 | $2,264 |
| Prednisolone Acetate | 73 | $2,161 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 14 | $1,779 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 73 | $1,363 |
| Latanoprost | 145 | $1,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $1,477 | $46,584102 claims |
| NovartisIlevro | $218 | $10,67130 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $148 | $4,84714 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $19 | $3,28614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Pittsburgh
- Francis MahPittsburgh$1.2M
- Robert NoeckerPittsburgh$634K
- Srinivas KondapalliPittsburgh$215K
- Deepinder DhaliwalPittsburgh$170K
- Deval ParanjpePittsburgh$121K
- Ian ConnerPittsburgh$103K
- Vishal JhanjiPittsburgh$80K
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.